Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999605 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
Patients with occult T3a disease had less than half the risk of PCSM as those with cT3 disease, and a subset of those men had similar risk as patients with pathologic T2 disease. Therefore, it is possible that radiation-managed patients with low-grade/intermediate-grade T3a disease by magnetic resonance imaging only might not require long-term ADT. However, patients with occult T3b or high-grade occult T3a disease have similar PCSM as that of those presenting with cT3 disease, so they should be treated as aggressively, including long-course ADT when managed by radiation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Vinayak M.Sc., Kathryn T. B.S., Brandon A. B.S., David R. B.S., Yu-Wei B.S., Vidya B. A.B., Michelle D. B.S., Toni K. M.D., Karen E. M.D., M.H.Sc., M.P.H., Jim C. M.D., Christopher J. M.B.B.S., Quoc-Dien M.D., Paul L. M.D.,